Category Archives: Value Health

Economic Impact of Reducing Inappropriate Inhaled Corticosteroids Use in Patients With Chronic Obstructive Pulmonary Disease: ISPOR’s Guidance on Budget Impact in Practice.

Related Articles
Economic Impact of Reducing Inappropriate Inhaled Corticosteroids Use in Patients With Chronic Obstructive Pulmonary Disease: ISPOR’s Guidance on Budget Impact in Practice.
Value Health. 2019 Oct;22(10):1092… Continue reading

Posted in Value Health | Tagged | Leave a comment

Cost-Effectiveness of Sacubitril/Valsartan in Germany: An Application of the Efficiency Frontier.

Related Articles
Cost-Effectiveness of Sacubitril/Valsartan in Germany: An Application of the Efficiency Frontier.
Value Health. 2019 Oct;22(10):1119-1127
Authors: van der Pol S, de Jong LA, Vemer P, Jansen DEMC, Po… Continue reading

Posted in Value Health | Tagged | Leave a comment

Do Surrogate Endpoints Better Correlate with Overall Survival in Studies That Did Not Allow for Crossover or Reported Balanced Postprogression Treatments? An Application in Advanced Non-Small Cell Lung Cancer.

Related Articles

Do Surrogate Endpoints Better Correlate with Overall Survival in Studies That Did Not Allow for Crossover or Reported Balanced Postprogression Treatments? An Application in Advanced Non-Small Cell Lung Cancer.

Value Health. 2018 Jan;21(1):9-17

Authors: Hashim M, Pfeiffer BM, Bartsch R, Postma M, Heeg B

Abstract
BACKGROUND: In previous studies, correlation between overall survival (OS) and surrogate endpoints like objective response rate (ORR) or progression-free survival (PFS) in advanced non-small cell lung cancer (NSCLC) was poor. This can be biased by crossover and postprogression treatments.
OBJECTIVES: To evaluate the relationship between these two surrogate endpoints and OS in advanced NSCLC studies that did not allow for crossover or reported balanced post-progression treatments.
METHODS: A systematic review in patients with advanced NSCLC receiving second- and further-line therapy was performed. The relationship between the absolute difference in ORR or median PFS (mPFS) and the absolute difference in median OS (mOS) was assessed using the correlation coefficient (R) and weighted regression models. The analysis was repeated in predefined data cuts based on crossover and balance of postprogression treatments. When the upper limit of R’s 95% confidence interval (CI) was more than 0.7, the surrogate threshold effect (STE) was estimated.
RESULTS: In total, 146 randomized clinical trials (43,061 patients) were included. The mean ORR, mPFS, and mOS were 12.2% ± 11.2%, 3.2 ± 1.3 months, and 9.6 ± 4.1 months, respectively. The correlation coefficients of ORR and mPFS were 0.181 (95% CI 0.016-0.337) and 0.254 (95% CI 0.074-0.418), respectively, with mOS. Nevertheless, in trials that did not allow crossover and reported balanced postprogression treatments, the correlation coefficients of ORR and mPFS were 0.528 (95% CI 0.081-0.798) and 0.778 (95% CI 0.475-0.916), respectively, with mOS. On the basis of STE estimation, in trials showing significant treatment effect size of 41.0% or more ORR or 4.15 or more mPFS months, OS benefit can be expected with sufficient certainty.
CONCLUSIONS: Crossover and postprogression treatments may bias the relationship between surrogate endpoints and OS. Presented STE calculation can be used to interpret treatment effect on either ORR or PFS when used as primary endpoints.

PMID: 29304946 [PubMed – in process]

Continue reading

Posted in Value Health | Tagged , | Leave a comment

Results Of A Dutch Cost-Effectiveness Model Of Radium-223 In Comparison To Cabazitaxel, Abiraterone, And Enzalutamide In Patients With Metastatic Castration Resistant Prostate Cancer Previously Treated With Docetaxel.

Results Of A Dutch Cost-Effectiveness Model Of Radium-223 In Comparison To Cabazitaxel, Abiraterone, And Enzalutamide In Patients With Metastatic Castration Resistant Prostate Cancer Previously Treated With Docetaxel.
Value H… Continue reading

Posted in Value Health | Tagged , | Leave a comment

Network Meta-Analysis of Survival Data Using Fractional Polynomials – an Example with First Line Metastatic Renal cell cancer Treatments.

Related Articles

Network Meta-Analysis of Survival Data Using Fractional Polynomials – an Example with First Line Metastatic Renal cell cancer Treatments.

Value Health….

Continue reading

Posted in Value Health | Tagged | Leave a comment

Cost-Effectiveness analysis of Quadrivalent Versus trivalent Influenza Vaccination In Germany – Linking a Dynamic Transmission Model with Health and Economic Outcomes.

Related Articles

Cost-Effectiveness analysis of Quadrivalent Versus trivalent Influenza Vaccination In Germany – Linking a Dynamic Transmission Model with Health and Economic Outcomes. …

Continue reading

Posted in Value Health | Tagged | Leave a comment

Recurrent Laryngeal Carcinoma Pet Study (Relaps): Cost Analysis Of 18f-Fdg Pet In Patients With Suspected Recurrent Laryngeal Cancer Previously Treated With Radiotherapy.

Related Articles

Recurrent Laryngeal Carcinoma Pet Study (Relaps): Cost Analysis Of 18f-Fdg Pet In Patients With Suspected Recurrent Laryngeal Cancer Previously Treated With Radiotherapy. …

Continue reading

Posted in Value Health | Tagged | Leave a comment

Early Economic Evaluation of A Hypothetical Perfect Test for Predicting The Effectiveness of Implantable Pacemaker-Defibrillator Devices (Crt-D) In Patients With Heart Failure.

Related Articles

Early Economic Evaluation of A Hypothetical Perfect Test for Predicting The Effectiveness of Implantable Pacemaker-Defibrillator Devices (Crt-D) In Patients With Heart…

Continue reading

Posted in Value Health | Tagged | Leave a comment

Dabigatran For The Treatment And Secondary Prevention Of Venous Thromboembolism.

Related Articles

Dabigatran For The Treatment And Secondary Prevention Of Venous Thromboembolism.

Value Health. 2015 Nov;18(7):A393

Authors: Stevanovic J,…

Continue reading

Posted in Value Health | Tagged | Leave a comment

Economic Burden Of Acute Myocardial Infarction In Vietnam.

Related Articles

Economic Burden Of Acute Myocardial Infarction In Vietnam.

Value Health. 2015 Nov;18(7):A389

Authors: Nguyen TP, Nguyen T, Postma M

Continue reading

Posted in Value Health | Tagged | Leave a comment

Healthcare Resource Utilisation Among Chronic Spontaneous/Idiopathic Urticaria Patients- Findings From The First International Burden of Illness Study (Assure-Csu).

Related Articles

Healthcare Resource Utilisation Among Chronic Spontaneous/Idiopathic Urticaria Patients- Findings From The First International Burden of Illness Study (Assure-Csu). …

Continue reading

Posted in Value Health | Tagged | Leave a comment

Work Productivity and Activity Impairment Among Chronic Spontaneous/Idiopathic Urticaria Patients: ResultsFrom The First International Burden of Illness Study (Assure-Csu).

Related Articles

Work Productivity and Activity Impairment Among Chronic Spontaneous/Idiopathic Urticaria Patients: ResultsFrom The First International Burden of Illness Study (Assure-Csu). …

Continue reading

Posted in Value Health | Tagged | Leave a comment

First Real-World Study Assessing Health Utility Values For Chronic Spontaneous/Idiopathic Urticaria Using The Eq-5d.

Related Articles

First Real-World Study Assessing Health Utility Values For Chronic Spontaneous/Idiopathic Urticaria Using The Eq-5d.

Value Health. 2015 Nov;18(7):A425

Continue reading

Posted in Value Health | Tagged | Leave a comment

Do European Patients Have A Shared Preference For The Benefits And Risks Of Medicines?

Related Articles

Do European Patients Have A Shared Preference For The Benefits And Risks Of Medicines?

Value Health. 2015 Nov;18(7):A469

Authors: Beyer A,…

Continue reading

Posted in Value Health | Tagged | Leave a comment

Impact of Drug’s Presentation on Patients’ Perception of Treatment’s Risks & Benefits Through New Ordinal Gee Modelling Method: Results from Imi Protect Wp6.

Related Articles

Impact of Drug’s Presentation on Patients’ Perception of Treatment’s Risks & Benefits Through New Ordinal Gee Modelling Method: Results from Imi Protect Wp6.

Continue reading

Posted in Value Health | Tagged | Leave a comment

Preference Elicitation On Benefits And Risks Of Medicines Using A Discrete Choice Experiment.

Related Articles

Preference Elicitation On Benefits And Risks Of Medicines Using A Discrete Choice Experiment.

Value Health. 2015 Nov;18(7):A469

Authors: Beyer…

Continue reading

Posted in Value Health | Tagged | Leave a comment

Comparative Cost-Effectiveness of Drugs in Early Versus Late Stages of Cancer; Review of the Literature and a Case Study in Breast Cancer.

Related Articles

Comparative Cost-Effectiveness of Drugs in Early Versus Late Stages of Cancer; Review of the Literature and a Case Study in Breast Cancer.

Value Health….

Continue reading

Posted in Value Health | Tagged | Leave a comment

Value Judgment of Health Interventions From Different Perspectives: Arguments and Criteria.

Related Articles

Value Judgment of Health Interventions From Different Perspectives: Arguments and Criteria.

Value Health. 2015 Nov;18(7):A550

Authors: Vermeulen…

Continue reading

Posted in Value Health | Tagged | Leave a comment

Assesing The Net Fiscal Consequences Of Tobacco Use In A High Consumption And High Tobacco Tax Country: The Case Of Greece.

Related Articles

Assesing The Net Fiscal Consequences Of Tobacco Use In A High Consumption And High Tobacco Tax Country: The Case Of Greece.

Value Health. 2015…

Continue reading

Posted in Value Health | Tagged | Leave a comment

A Systematic Literature Review of The Economic Implications of Acute Bacterial Skin And Skin Structure Infections (Absssis).

Related Articles

A Systematic Literature Review of The Economic Implications of Acute Bacterial Skin And Skin Structure Infections (Absssis).

Value Health. 2015…

Continue reading

Posted in Value Health | Tagged | Leave a comment